Please login to the form below

Not currently logged in
Email:
Password:

Testing for new Alzheimer's treatment

American pharma company Eli Lilly & Co announced on March 31 the start of a phase III clinical trial for a new Alzheimer's treatment.
American pharma company Eli Lilly & Co announced on March 31 the start of a phase III clinical trial for a new Alzheimer's treatment.

The new treatment, known as LY450139, will be tested in the IDENTITY (interrupting Alzheimer's Dementia by Evaluating Treatment of Amylold Pathology) trial.

Lilly claims that LY450139 could slow the onset of mild-to-moderate Alzheimer's disease and give patients preserved functionality and quality of life.

During the course of the double-blind, placebo-controlled study, 1,500 patients will take part in the trials in the US and 21 additional countries over the course of 21 months.

Dr Eric Siemers, medical director of Alzheimer's disease research for Lilly, said: "Alzheimer's is a devastating disease that destroys brain cells, affecting everything from a patient's memory to their work and social life. Currently available medications treat the symptoms of Alzheimer's disease but have not been shown to change its underlying progression, creating an urgent unmet medical need."

LY450139 is an investigational gamma secretase inhibitor and has been developed to counteract the degenerative progression of Alzheimer's by excreting an enzyme that creates a sticky protein.

Siemers said that Lilly hopes, "that LY450139 will represent an advance in the attempt to slow the progression of this fatal disease".

31st March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics